Interventional Study of Vosoritide for the Treatment of Children With Hypochondroplasia
This research study is looking at a new medicine called vosoritide for children and teenagers aged 3 to 17 who have a condition called hypochondroplasia. This condition is a type of short stature, meaning bones don't grow as much as they should. The main goal is to see if vosoritide can help these children grow taller over a period of 52 weeks (about one year). Participants will be split into two groups by chance: one group will receive vosoritide, and the other will receive a dummy medicine called a placebo. Neither the participants, their families, nor the study doctors will know who is getting which treatment. Both medicines will be given as a daily injection just under the skin. We hope to find out if vosoritide is a helpful and safe treatment option for children with hypochondroplasia.
نظرة سريعة
ما هو موضوع هذه الدراسة؟
This study is a very important step in understanding and potentially treating hypochondroplasia, a condition that affects how bones grow, leading to shorter stature. Doctors are always looking for new and better ways to help children with growth conditions. This particular study is focusing on a medicine called vosoritide, which has shown promise in earlier research.
The main idea is to see if giving vosoritide daily can help children with hypochondroplasia grow more over a year than if they weren't taking the medicine. To do this fairly, the study will involve two groups: one receiving vosoritide and another receiving a 'placebo', which looks exactly like the medicine but contains no active drug. This is a common and important way to test new medicines, as it helps doctors be sure that any changes they see are due to the medicine itself and not other factors. Everyone involved in the study – participants, their families, and the medical team – won't know who is getting which treatment until the study is over. This is called a 'double-blind' study and helps make the results as reliable as possible.
Participation in a study like this is voluntary and can be a way for families to contribute to medical knowledge and potentially help their own child or other children with hypochondroplasia in the future. The information gathered will help doctors decide if vosoritide could become a widely used treatment for this condition.
النقاط الرئيسية
- The study tests a medicine called vosoritide for hypochondroplasia in children.
- It aims to see if the medicine helps children grow taller.
- Participants will receive either vosoritide or a dummy medicine (placebo).
- Study lasts 52 weeks with daily injections and regular check-ups.
- It's for children aged 3 to almost 18 with a confirmed diagnosis of hypochondroplasia.
- المشاركة طوعية، ويمكنك الانسحاب في أي وقت.
من قد يكون مؤهلاً؟
To join this study, children must be between 3 and almost 18 years old. They need to have a confirmed diagnosis of hypochondroplasia through a genetic test. Also, their height should be noticeably shorter than average for their age and sex.
There are also some reasons why a child might not be able to join. For example, if they have another condition causing short stature, or if they've recently taken certain growth-affecting medicines like growth hormone. Children who need surgery on their bones during the study period, or who have had certain experimental treatments before, would also not be able to take part. This ensures the study includes the right people to get clear results.
Girls aged 10 or older, or who have started their periods, will need to have a pregnancy test. If they are sexually active, they must agree to use effective contraception during the study. This is a standard safety measure for many clinical trials.
هل يمكن أن تناسبك هذه الدراسة؟
أجب عن هذه الأسئلة السريعة لترى ما إذا كنت مؤهلاً. هذا دليل فقط - الفريق البحثي هو الذي يتخذ القرار النهائي.
- Is my child between 3 and almost 18 years old?
- Does my child have a confirmed genetic diagnosis of hypochondroplasia?
- Is my child significantly shorter than average for their age and sex?
- Has my child NOT received growth hormone or other similar growth treatments recently?
- Is my child generally healthy, without other serious medical conditions?
- For girls aged 10+ or who have periods: Are they not pregnant and willing to use contraception if sexually active?
ماذا يتضمن المشاركة؟
If your child joins the study, they will receive either the study medicine, vosoritide, or a placebo (dummy medicine) as a daily injection just under the skin. You will be taught how to give these injections at home. The treatment will last for 52 weeks, which is about one year.
Throughout the study, your child will have regular check-ups at the hospital or clinic. These appointments will involve blood tests, measurements of their height and weight, and other assessments to monitor their growth and general health. The doctors will also check for any side effects from the medicine.
After the 52 weeks of treatment, there will likely be some follow-up visits to ensure your child's health continues to be stable. The total duration of active participation, including follow-up, will be explained fully by the study team.
المخاطر والفوائد المحتملة
المواقع (23)
- Nemours Alfred I. DuPont Hospital for Childrenالرمز البريدي المؤكدويلمنجتون، الولايات المتحدة
- Children's National Medical Centerالرمز البريدي المؤكدواشنطن العاصمة، الولايات المتحدة
- مستشفى آن وروبرت إتش. لوري للأطفال في شيكاغوالرمز البريدي المؤكدشيكاغو، الولايات المتحدة
- Medical College of Wisconsinالرمز البريدي المؤكدميلووكي، الولايات المتحدة
- Murdoch Children's Research Instituteالرمز البريدي المؤكدباركفيل، أستراليا
- University of Alberta Stollery Children's Hospitalالرمز البريدي المؤكدإدمونتون، كندا
- SickKids - The Hospital for Sick Childrenالرمز البريدي المؤكدتورونتو، كندا
- Centre Hospitalier Universitaire Sainte-Justineالرمز البريدي المؤكدمونتريال، كندا
- Hospices Civils de Lyon - Hopital Femme Mere Enfantالرمز البريدي المؤكدليون، فرنسا
- Hopital de la Timoneالرمز البريدي المؤكدمرسيليا، فرنسا
- Hopital Necker-Enfants Maladeالرمز البريدي المؤكدباريس، فرنسا
- المستشفى الجامعي في تولوزالرمز البريدي المؤكدتولوز، فرنسا
أسئلة شائعة
What is hypochondroplasia?
It's a genetic condition where bones don't grow to their usual length, leading to shorter stature, often with shorter arms and legs.
What is vosoritide?
Vosoritide is a new medicine being tested to see if it can help improve bone growth in children with conditions like hypochondroplasia.
ما هو الدواء الوهمي؟
A placebo is a 'dummy' medicine that looks like the real thing but has no active drug. It helps doctors know if the real medicine is actually working.
Will my child know if they are getting the real medicine or the placebo?
No, neither your child, you, nor the doctors will know. This is a 'double-blind' study to keep the results fair.
كيف يتم إعطاء الدواء؟
The medicine (or placebo) is given as a daily injection just under the skin, similar to an insulin injection.
كيفية معرفة المزيد
تحدث دائمًا إلى طبيبك العام أو الأخصائي قبل اتخاذ قرار بالمشاركة في دراسة.
نقاش
مناقشة المجتمع
مدعوم من منتدانا في community.patient.info. يرجى التحلي بالاحترام — هذه ليست نصيحة طبية.